Alto Neuroscience (NYSE:ANRO) Trading Down 6.3% - Time to Sell?

Key Points

• Shares fell 6.3% mid-day to $21.11 (low $20.89) on lighter volume — 108,239 shares vs. a 255,021 average — with a market cap of about $673 million and 50-/200‑day moving averages of $19.40/$15.09.
• Analyst sentiment is mixed: the stock has a consensus rating of "Moderate Buy" with a $35.14 target, but recent downgrades and price-target cuts from several firms (including Weiss and Wall Street Zen) sit alongside multiple buy ratings.
• Alto is a clinical‑stage precision neuroscience company that beat quarterly EPS estimates (‑$0.45 vs. ‑$0.56) while forecasting a FY EPS of ‑2.54, and several institutional investors (Vestal Point, Perceptive, Commodore) significantly increased their stakes.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) shares fell 6.3% during mid-day trading on Tuesday . The stock traded as low as $20.89 and last traded at $21.11. 108,239 shares were traded during mid-day trading, a decline of 58% from the average session volume of 255,021 shares. The stock had previously closed at $22.53.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ANRO. Weiss Ratings reiterated a "sell (e+)" rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Wall Street Zen cut Alto Neuroscience from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Wedbush decreased their price objective on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating for the company in a research note on Thursday, April 2nd. Jefferies Financial Group reiterated a "buy" rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. Finally, JonesTrading decreased their price objective on Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating for the company in a research note on Thursday, April 2nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.14.

Alto Neuroscience Stock Performance

The firm has a 50 day moving average of $19.40 and a two-hundred day moving average of $15.09. The stock has a market cap of $672.77 million, a PE ratio of -9.71 and a beta of 2.01. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. Research analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP lifted its stake in Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock valued at $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Commodore Capital LP purchased a new stake in Alto Neuroscience in the fourth quarter valued at approximately $32,453,000. Perceptive Advisors LLC lifted its stake in Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company's stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Armistice Capital LLC lifted its stake in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company's stock valued at $6,577,000 after buying an additional 12,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company's stock valued at $4,444,000 after buying an additional 20,702 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.